What can be learned about biology from massive datasets, and can that information unveil opportunities for new therapeutics? This is the approach by Turbine. Today's podcast discusses Turbine's approach with Dr. Dan Veres, CSO and Co-Founder of the company. He describes how data sets from multi-omics analysis are merged and analyzed to identify potential drug targets. and in silico information informs wet lab tests. The outcome is new therapeutics to treat recalcitrant disease. Webiste: www.turbine.ai